SASSARI, Italy, PRINCETON, N.J. & BUDAPEST, Hungary–(Business Wire)–
ViroStatics, srl, an Italian-US biopharmaceutical company today announced the
formation of a strategic partnership with Vichem Chemie of Budapest, Hungary to
identify, synthesize, screen, and develop the next generation of
AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) for the treatment of
HIV/AIDS and other chronic diseases.
Vichem Chemie is a Hungarian biotech research company focusing upon the field of
kinase inhibitors, one of the fastest growing segments within the pharmaceutical
industry with applications in oncology, autoimmune diseases and other unmet
medical needs. ViroStatics has brought the first-in-class AV-HALT, VS411, into
Phase II development. AV-HALTS are a new class of drugs that combine direct
anti-viral activity with a reduction in the chronically elevated immune system
activation that is now known to play a major role in the progression of HIV
disease, ultimately leading to AIDS.
“We are extremely pleased to be working with Vichem Chemie to discover valuable
new AV-HALT drugs,” explained Franco Lori, MD, President and CEO of ViroStatics.
“Vichem`s expertise, know-how and credibility in the area of in vitro discovery
of novel drug families are well-known. Our new partnership brings together both
companies` substantial intellectual properties and significant libraries of
Kinase Inhibitors.”
“The expertise of ViroStatics in translating basic discoveries into clinical
applications -from the bench to the bed side – is well appreciated,” added
Gyorgy Keri, PhD and CEO of Vichem Chemie. “The Companies` strengths are both
complimentary and synergistic. We look forward to a successful partnership to
identify new and exciting compounds that ViroStatics will develop into important
new therapies against HIV/AIDS and other chronic diseases.”
“The new class of AV-HALTs represents a novel approach to the treatment of HIV
based upon the most recent discoveries in the field of viral pathogenesis,” said
Richard B. Pollard, MD, Professor of Medicine and Chief of the Division of
Infectious Diseases, University of California Davis Health System. “ViroStatics
was the first to achieve Proof-of-Principle for the AV-HALTs with the two-drug
combination product, VS411. The collaboration between ViroStatics and Vichem
Chemie is expected to lead to the second generation of AV-HALTs where both
antiviral activity and reduction of excessive immune activation are combined in
a single molecule.”
About Vichem Chemie
Vichem Chemie was established in 1999. Its predecessor, Biosignal LTD, was
founded in 1991. Vichem performs advanced medicinal chemistry in the kinase
inhibitory field using its unique Nested Chemical Library (NCL) technology. NCL
includes more than 500 scaffolds and contains inhibitors against 124 kinases.
Utilizing the NCL, Master Key, Pharmacophore modelling, and Scaffold-hopping
technologies, Vichem provides patentable lead compounds against selected kinases
in five research cycles and performs selectivity profiling and off-target
identification with target fishing technology. Vichem has a
pharmacodiagnostics-based drug discovery program and develops preclinical
candidates with lead optimization for efficacy and ADMET. Vichem has
developmental candidates for HIV, Influenza, Tuberculosis and five oncological
kinase targets.
About ViroStatics
ViroStatics srl, an Italian pharmaceutical company with operations in Sassari,
Italy and Princeton, NJ, discovers and develops novel therapeutics to address
significant medical needs in HIV/AIDS, chronic infections and related fields.
The company is developing its lead product, VS411, as the first fixed-dose
combination of two drugs that not only decrease HIV replication but also protect
and conserve the immune system. ViroStatics recently announced its intention to
merge with Genetic Immunity to form Immunacia – a multinational
biopharmaceutical company with Business/Medical/Legal operations in the United
States and research facilities in Hungary and Italy – dedicated to developing
novel treatments that partner with the immune system to improve human health.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6323210〈=en
Vichem Chemie Research Ltd.
Prof. György Kéri
Chief Executive Officer
Phone: +36-1-487-2080
Fax: +36-1-799-9990
gykeri@vichem.hu
www.vichem.hu
or
ViroStatics, srl
Michael Stevens, PharmD
+1-609-951-2206
Chief Development Officer
m.stevens@virostatics.com
www.virostatics.com
Copyright Business Wire 2010